Cargando…
Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has disrupted health care and has resulted in high mortality rates.(1) Vaccination is an international priority to mitigate the risks of SARS-CoV-2. The initial trials for development of SARS-CoV-2 vaccines excluded individual...
Autores principales: | Long, Millie D., Weaver, Kimberly N., Zhang, Xian, Chun, Kelly, Kappelman, Michael D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the AGA Institute
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826602/ https://www.ncbi.nlm.nih.gov/pubmed/35150924 http://dx.doi.org/10.1016/j.cgh.2022.01.056 |
Ejemplares similares
-
Su1492: STRONG HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE ADDITIONAL DOSE AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kappelman, Michael, et al.
Publicado: (2022) -
Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease
por: Kappelman, Michael D., et al.
Publicado: (2021) -
Risks of Development of COVID-19 Among Patients With Inflammatory Bowel Disease: A Comparative Assessment of Risk Factors for Incident Infection
por: Long, Millie D, et al.
Publicado: (2022) -
A Patient-Prioritized Agenda for Information Needs During the COVID-19 Pandemic: A Qualitative Study of Patients With Inflammatory Bowel Disease
por: Long, Millie D, et al.
Publicado: (2021) -
Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases
por: Brenner, Erica J., et al.
Publicado: (2021)